TP53 and medulloblastoma: Patients with Group 3 medulloblastoma (MB), especially those who have tumors that harbor MYC amplification or present with metastasis (along with a subset of SHH tumors with TP53 mutation), have the worst survival outcome, while those with WNT subgroup tumors have the best survival [2].